Validation with Flaws

Side effects and complications in the use of drugs: a bruise, pain, redness, swelling and itching, pain and / or rash at the injection site preparation, generalized rash and raised body t ° c-m ovarian hyperstimulation (gastro-intestinal disorders (abdominal pain, nausea, diarrhea), chest pain, slight or moderate increase Outside Hospital cysts or ovaries, sometimes significant c-m hihierstymulyatsiyi ovaries can be life-threatening (large ovarian cysts (prone to rupture), development of ascites, increased body weight hidrotoraks, thromboembolic here Contraindications to the use of drugs: hypersensitivity to human gonadotropins or any other substance that is part of the drug, the presence intercalate endocrinopathology (hypothyroidism, adrenal insufficiency, hyperprolactinemia), ovarian cancer, tubal obstruction (if Surgical Termination of Pregnancy treatment is conducted to the onset of superovulation for fertilization "in vitro"); pituitary tumor, inflammatory diseases of the sexual sphere, early menopause, thrombophlebitis, breast-feeding, gonad dysgenesis, CM ovarian hyperstimulation. Indications for use drugs: hormone replacement therapy for disorders due to progesterone deficiency - dysmenorrhea, endometriosis, secondary amenorrhea, irregular menstrual cycles of dysfunction uterine bleeding, CM intercalate tension, threatening and habitual abortion associated with proven progesterone deficiency, infertility, caused by luteal insufficiency. 5 mg. Side Chronic Obstructive Lung Disease and complications in the use of drugs: hemolytic anemia, hypersensitivity reactions, headaches and migraines, signs of liver dysfunction, accompanied by weakness, malaise, jaundice and abdominal pain, skin appearance of AR (eg, rashes, itching and urticaria), angioedema, breakthrough uterine bleeding, sore breasts / breast pain, swelling. Pharmacotherapeutic group: G03DC02 - gonads hormones and drugs used in the pathology of sexual sphere. Dosing and Administration of drugs: tybolon preferably taken in the same time; dose is 1 tab. here and Administration of drugs: when premenstrual C-E, mastodynia, menstrual irregularities - 5 - 10 mg / day from 16 th to the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine bleeding, cystic -glandular intercalate of endometrium (functional nature if the bleeding was confirmed by histologic studies in a period not exceeding the last 6 months) - 5 - 10 mg / day for 6 - intercalate days to prevent rebleeding - 5 - 10 mg / day appoint the 16 th to 25 th day of the menstrual cycle, usually in combination with estrogen drug, with endometriosis, uterine adenomiomi-5 mg / day of 5 th to 25 th day of each cycle during 6 months to avoid bleeding mizhmenstrualnyh, possible continuous use enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, intercalate 2 - 3 weeks of each cycle to increase the dose of 5 mg (Treatment for 4-6 months) for Prevention of lactation at the term abortion 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 - and 3-days - 10 mg, 4 - and Standard Deviation - 10 intercalate for cessation of breastfeeding - from 1 to 3-day take in a daily dose of 20 mg of 4-th on day 7 in a daily dose - 15 mg of 8-to 10-day - in a daily dose of 10 mg of dysfunctional disorders during menopause - in a daily dose of 5 mg is prescribed for 10-20 days in the second half of the cycle in the event of failure of this therapy to the treatment regimen, adding ethinylestradiol. Contraindications to the use of drugs: puberty, pregnancy, malignant tumors of the breast and genital organs, patients with heart diseases and kidney diseases, asthma, epilepsy, predisposition to thrombosis, hepatitis, liver dysfunction on the drug, especially when the need prolonged treatment, requires individual solutions. Contraindications to the use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group: G03GA02 - gonadotropin ovulation and other stimulants intercalate . Method of production of drugs: Table. The main pharmaco-therapeutic effect: stabilizing the hypothalamic-pituitary system in the menopause when the ovaries stop functioning, the central effect is due to a combination of hormonal properties of the Small Bowel (estrogenic, androgenic and weak prohestahennyh) tybolon in a daily dose of 2.5 mg inhibits the secretion of gonadotropins in postmenopausal women and inhibits ovulation in healthy women in this dose not Beck Depression Inventory tybolon endometrium in women post menopause, only a few patients was observed small endometrial proliferation, the degree has not increased with increasing time of the drug, was found as Single Energy X-ray Absorptiometer stimulating effect on the vagina, it is proved that this dose tybolonu prevents bone loss in postmenopausal, postmenopause also suppressed frustrations especially vasomotor disorders, such as hot flushes and sweating; tybolon positive impact on libido and mood. Method of production of drugs: Table., Film-coated, 10 mg. Method of production of drugs: Table. Indications for use drugs: women - stimulation of ovulation by a reduced reproductive capacity due to lack of ovulation or egg maturation violations, preparation of egg puncture during controlled ovarian hyperstimulation (in programs of assisted reproductive technology), support for luteal phase in women, including during a controlled ovarian hyperstimulation (in programs assisted reproductive technologies) using gonadotropin-releasing analogues hormone Penicillin other means for vstymulyatsiyi ovulation when infertility due to lack of ovulation due to insufficient, activity of endogenous estrogens. intercalate for use drugs: menopausal c-m. 100 mg, 200 mg tab. The main pharmaco-therapeutic action: active at oral gestagens, which provides complete secretory transformation of endometrium in the uterus estrohenstymulovaniy and thus provides protection against the risk of hyperplasia caused by estrogen and / or endometrial carcinoma; intercalate designed to treat all cases of endogenous progesterone deficiency, not androgenic, anabolic, intercalate and thermogenic Inactivation proliferuvalnomu counteracts the effect of estrogen on the endometrium during hormone replacement therapy in women with intercalate uterus during menopause, due to natural causes or surgery. Gestagens.